Form 4: Xeris Biopharma Legal Officer Sells Shares Under 10b5-1 Plan

Xeris Biopharma's Chief Legal Officer, Beth Hecht, sold 16,667 shares of common stock for a weighted average price of $7.3976 per share pursuant to a Rule 10b5-1 trading plan.

Summary

• Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, Inc. (XERS), reported a sale of common stock.
• The transaction involved the disposition of 16,667 shares of common stock.
• The shares were sold on November 11, 2025, at a weighted average price of $7.3976 per share.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
• Following this transaction, Beth Hecht directly beneficially owns 1,336,843 shares of common stock.
• The shares were sold in multiple transactions within a price range of $7.290 to $7.750.

Sentiment

Score: 5

Explanation: The filing reports a routine insider stock sale executed under a Rule 10b5-1 plan, which is a neutral event. It does not indicate positive or negative company performance or significant strategic shifts.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction designed to avoid accusations of trading on material non-public information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived by some investors as a lack of confidence, though this is often a routine part of executive compensation and diversification.

Future Outlook

NA

Management Comments

• The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
• The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.290 to $7.750, inclusive.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are a common occurrence in publicly traded companies. These plans allow insiders to sell a predetermined number of shares at a predetermined time or price, providing a defense against insider trading allegations and facilitating personal financial planning.

Corporate Governance

Stakeholder Impact

• Shareholders: A routine insider sale under a 10b5-1 plan typically has minimal direct impact on shareholders, as it is a pre-planned event. However, some investors may view any insider selling, regardless of the plan, with slight caution.

Key Dates

Keywords

Xeris Biopharma, XERS, Insider Trading, Form 4, Stock Sale, Beth Hecht, 10b5-1 Plan, Chief Legal Officer, Corporate Secretary, Equity Transaction